The results were described as “really encouraging” by Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy. The data were released early by the companies after details from the phase 3 clinical trial were leaked on social media on…
register or log in to get more services such as weather report, extended news articles and web search